Verbena Attenuates Adriamycin-Induced Renal Tubular Injury via Inhibition of ROS-ERK1/2-NLRP3 Signal Pathway

Chronic kidney disease (CKD) has become a global public health problem. Tubular epithelial cell injury plays a vital role in the progression and prognosis of CKD. Therapies to protect tubular cells is the key to delaying CKD progression. Our study found that verbena, a natural traditional Chinese he...

Full description

Saved in:
Bibliographic Details
Published in:Evidence-based complementary and alternative medicine 2022-09, Vol.2022, p.1-11
Main Authors: Zhou, Yicen, Wu, Qijing, Du, Zhenfang, Huang, Min, Gao, Kun, Ma, Xiaowei, Zhang, Hui, Qiang, Sheng, Sun, Wei
Format: Article
Language:English
Subjects:
Apoptosis
Cell disruption
Cell injury
Cell viability
Chinese medicine
Chromatography
Epithelial cells
Extracellular signal-regulated kinase
Herbal medicine
Hospitals
Kidney diseases
Kinases
Laboratory animals
Oxidation
Oxidative stress
Proteins
Public health
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Chronic kidney disease (CKD) has become a global public health problem. Tubular epithelial cell injury plays a vital role in the progression and prognosis of CKD. Therapies to protect tubular cells is the key to delaying CKD progression. Our study found that verbena, a natural traditional Chinese herb, has a potential reno-protective role in kidney diseases. However, the detailed mechanism remains unknown. In the current study, we employed adriamycin (ADR)-induced renal tubular cell injury to mimic the conditions of tubular injury in vitro. Results showed that total aqueous exact of verbena (TAEV) ameliorated ADR-induced cell disruption, loss of cellular viability, and apoptosis via inhibition of ROS-ERK1/2-mediated activation of NLRP3 signal pathway, suggesting that TAEV serves as a promising renoprotective agent in delaying the progression of CKD, while ROS-ERK1/2-mediated NLRP3 signal pathway might be a novel target in treating kidney diseases.
ISSN:1741-427X
1741-4288
DOI:10.1155/2022/7760945